Note 11 - Stock-Based Compensation - Stock-Based Compensation Expense by Plan (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Stock-based compensation expense	$ 1,694	$ 1,143	$ 3,104	$ 2,174
Lucid Diagnostics 2018 Equity Plan [Member] \| Cost of Revenue [Member]
Stock-based compensation expense	14	38	127	71
Lucid Diagnostics 2018 Equity Plan [Member] \| Sales and Marketing [Member]
Stock-based compensation expense	336	245	589	466
Lucid Diagnostics 2018 Equity Plan [Member] \| General and Administrative [Member]
Stock-based compensation expense	1,166	740	2,070	1,341
Lucid Diagnostics 2018 Equity Plan [Member] \| Research and Development [Member]
Stock-based compensation expense	165	119	296	214
PAVmed 2014 Equity Plan [Member] \| Cost of Revenue [Member]
Stock-based compensation expense	0	0	1	38
PAVmed 2014 Equity Plan [Member] \| Sales and Marketing [Member]
Stock-based compensation expense	2	0	4	19
PAVmed 2014 Equity Plan [Member] \| General and Administrative [Member]
Stock-based compensation expense	3	1	5	1
PAVmed 2014 Equity Plan [Member] \| Research and Development [Member]
Stock-based compensation expense	$ 8	$ 0	$ 12	$ 24